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Abstract  Some  reports  have  outlined  many  different  treatment  strategies  for  superior  oblique
myokymia (SOM)  that  attempt  to  reduce  or  eliminate  patients’  symptoms  of  monocular  oscil-
lopsia and/or  diplopia.  Most  treatment  strategies  have  focused  solely  on  oral  medications  or
invasive surgery.  The  following  is  a  current  and  critical  review  of  SOM  along  with  its  clinical  ﬁnd-
ings/symptoms,  demographics,  theories  of  its  pathogenesis,  management/treatment  options,
new observations  in  SOM,  as  well  as  a  case  report  to  highlight  a  relatively  novel  idea  for  the
treatment  of  SOM:  topical  timolol  eye  drops.  It  also  highlights  evidence  of  a  new  ‘‘localized
theory’’ regarding  topical  -blockers’  mechanism  of  action  in  SOM  compared  to  the  previous
systemic hypothesis  proposed  in  1994.
The  case  report  shows  a  29-year-old  female  patient  who  suffered  with  SOM  symptoms  for
8--10 years  and  then  experienced  a  worsening  of  her  symptoms  shortly  postpartum.  The  patient
was prescribed  topical  timolol  eye  drops  by  the  author  in  the  affected  eye  based  on  one  case
report12 from  1994,  which  completely  eliminated  her  symptoms  within  1--2  days  of  starting
the treatment  with  any  recurrence  with  the  daily  use  of  the  drop  at  the  time  of  this  article.
Given the  robust  effect  in  this  case,  topical  timolol  may  be  a  potentially  useful  drug  in  the
management  of  SOM  given  its  affordability  and  safer  side  effect  proﬁle  in  comparison  to  the
oral medications  traditionally  used  in  SOM.
© 2013  Spanish  General  Council  of  Optometry.  Published  by  Elsevier  España,  S.L.  All  rights
reserved.
PALABRAS  CLAVE
Mioquimia  del  oblicuo
Tratamiento  de  la  oscilopsia  monocular  secundaria  a  la  mioquimia  del  oblicuo
superior:  revisión  y  uso  potencial  de  Timolol  tópicosuperior;
Oscilopsia; Resumen  Los  estudios  reportados  de  casos  de  mioquimia  del  oblicuo  superior  (MOS)  hanOscilopsia  monocular;
Nervio  troclear;
puesto de  maniﬁesto  diferentes  estrategias  de  tratamiento  que  tratan  de  reducir  o  eliminar  los
síntomas asociados  de  oscilopsia  monocular  y/o  diplopía.  Muchas  estrategias  de  tratamiento
se han  centrado  únicamente  en  medicaciones  orales  o  procedimientos  quirúrgicos  invasivos.
El presente  artículo  es  una  revisión  crítica  de  la  MOS  en  relación  a  sus  hallazgos/síntomas
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craneal;
Mioquimia  troclear
clínicos,  datos  demográﬁcos,  teorías  de  su  patogénesis,  opciones  de  manejo/tratamiento,  y
nuevas observaciones  en  cuanto  a  MOS,  incluyendo  la  descripción  de  un  caso  que  muestra  una
idea relativamente  nueva  de  tratamiento  del  MOS:  gotas  oculares  de  Timolol  tópico.  También
subraya la  evidencia  de  una  nueva  ‘‘teoría  localizada’’  referente  al  mecanismo  de  acción  de
los -bloqueantes  tópicos  en  la  MOS,  en  comparación  a  la  hipótesis  sistémica  previa  propuesta
en 1994.
El caso  reportado  hace  referencia  a  una  paciente  de  29  an˜os  que  padeció  los  síntomas  de
MOS durante  8-10  an˜os,  y  experimentó  un  empeoramiento  de  dichos  síntomas  poco  después
del periodo  post-parto.  El  autor  prescribió  a  la  paciente  gotas  de  Timolol  tópico  en  el  ojo
afectado,  basándose  en  el  reporte  de  un  caso12 de  1994,  lo  que  eliminó  completamente  los
síntomas a  los  1-2  días  de  inicio  del  tratamiento,  sin  existir  a  fecha  de  este  artículo  ninguna
recurrencia  con  el  uso  diario  de  esta  medicación.  Dado  el  sólido  efecto  de  este  caso,  el  Timolol
tópico puede  constituir  un  medicamento  potencialmente  útil  para  el  tratamiento  de  la  MOS,
dada su  asequibilidad  y  el  perﬁl  de  seguridad  de  los  efectos  colaterales  en  comparación  a  las
medicaciones  orales  tradicionalmente  utilizadas  en  la  MOS.
© 2013  Spanish  General  Council  of  Optometry.  Publicado  por  Elsevier  España,  S.L.  Todos  los
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Introduction
Superior  oblique  myokymia  (SOM)  is  probably  best  described
as  an  intermittent  spontaneous  rhythmic  contraction  of  the
superior  oblique  muscle  presenting  as  rapid  and  small  ampli-
tude  intorsions  and  depressions  of  one  eye.  SOM  was  ﬁrst
described  by  Duane  in  1906  as  a  ‘‘unilateral  rotary  nys-
tagmus’’1--7;  however  in  1970,  Hoyt  et  al.  coined  the  term
‘‘superior  oblique  myokymia’’  which  is  used  most  commonly
today  to  describe  this  interesting  condition.2,3 Another  name
often  given  to  this  condition,  and  probably  considered  more
accurate,  is  ‘‘intermittent  uniocular  microtremor’’.4,6 Since
1970,  there  have  been  a  moderate  amount  of  articles,  case
reports,  and  studies  performed  to  gain  insight  into  how  best
to  diagnose,  treat,  and  manage  this  condition;  however,  the
overall  numbers  of  patients  successfully  treated  with  topical
-blockers/antagonists  is  very  low  overall  in  the  ophthalmic
literature.
Symptoms  of  SOM  typically  include  subjective  visual
disturbances  such  as  spontaneous  monocular  diplopia,
monocular  oscillopsia,  and  quivering/jumping  of  the
involved  eye.2--9,13,14,22,23 One  of  its  main  differentiating
points  is  its  monocular  nature.3--5,13,20,22,23,25 Signs  usual
involve  a  higher  frequency  (12--15  Hz),  lower  amplitude
(3◦--6◦),  unilateral,  intermittent  cyclic,  intorsion  and/or
depression  of  the  involved  eye  which  can  be  seen  upon
examination  by  the  observer  with  mild  to  moderate  mag-
niﬁcation  at  the  slit  lamp.2--4,9,15,21--23 Occasionally,  this
cyclic  intorting  movement  can  also  be  seen  during  fundo-
scopic/ophthalmoscopic  examination.2,21 The  fast  phase
occurs  during  intorsion  and  in  many  cases  the  SOM  can  be
increased  by  having  the  patient  look  in  the  direction  of  the
superior  oblique  (down  and  in)  which  is  most  troublesome
when  a  person  is  reading,  driving,  or  with  other  visually
demanding  work.3,4,6,20--23 Many  times  a  patient  will  know
the  exact  maneuver  that  will  trigger  an  attack  of  the
ocular  symptoms.4 These  intermittent,  recurrent  episodes
typically  occur  multiple  times  on  a  daily  basis.5,6,13,22Duration  of  symptoms  vary  dramatically  from  a  few  seconds
to  minutes;  however,  the  majority  of  attacks  seem  to
last  3--15  s.4--6,13,22,26 In  some  unfortunate  cases,  SOM  may
increase  in  duration  until  the  symptoms  are  present
s
o
s
andeﬁnitely,  although  this  seems  to  be  extremely
ncommon.4 Eye  movement  recordings  during  these
ttacks  have  shown  small  vertical  and  torsional  move-
ents  of  the  superior  oblique  muscle  which  are  conﬁned
olely  to  the  involved  superior  oblique  muscle  during
ach  attack.2,3,13,20,23 Occasionally,  an  ipsilateral  hyper-
horia/tropia  is  present,  which  can  be  elicited  via  the
lternating  and  unilateral  cover  tests,  indicating  an
nderaction  of  the  superior  oblique  muscle,4 which  can
ometimes,  but  not  always,  be  treated  with  a  prismatic
orrection  in  the  patient’s  habitual  prescription  using  base
own  prism  equal  to  the  magnitude  of  the  deviation  over
he  hyper-deviated  eye.8,22,23
SOM  appears  to  be  independent  of  age  as  cases  of
eenagers  through  older  patients  in  excess  of  60  years  of
ge  have  been  reported.2,3 Females  are  reportedly  about
--3  times  as  likely  as  males  to  suffer  from  SOM.11,13,25 The
verage  age  of  onset  is  estimated  to  be  34--37  years  old.22,25
here  appears  to  be  a  higher  chance  of  involvement  of
he  right  superior  oblique  in  comparison  to  the  left;  how-
ver,  the  underlying  reason  for  this  is  currently  unknown.21
eported  trigger  factors  and  associations  are  numerous.
tress  (mental  or  physical),  fatigue,  alcohol,  caffeine,  nico-
ine,  and  ﬂuorescent  lighting  have  all  been  reported  as
rigger  factors.13,22,23,26,28 Of  note,  some  reports  outline  that
ome  patients  have  members  of  their  families  with  a  diag-
osis  of  multiple  sclerosis  which  raises  the  question  of  a
ereditary  nature  or  a relationship  to  multiple  sclerosis,
lthough  this  association  is  also  unclear  and  only  speculative
t  this  point.2,3 A  history  of  head  trauma  has  been  reported
o  be  associated  with  SOM  in  many  cases,  although  trauma
s  not  a requirement  for  SOM.6,7,11,13,14,19,23,25 In  those  cases
f  SOM  with  a history  of  head  trauma,  the  symptoms  do  not
lways  start  immediately  after  trauma  but  may  occur  many
ears  later.6,7,11,13,14,19,23,25
Correct  diagnosis  is  most  important  in  these  patients  as
ost  of  their  symptoms,  although  troubling,  can  be  difﬁ-
ult  to  detect  during  a  routine  eye  exam  because  of  their
15poradic  and  intermittent  nature. In  most  cases,  a  thor-
ugh  case  history  and  attentive  listening  to  the  patients’
elf-described  symptoms  can  alert  the  medical  professional
nd  help  to  narrow  down  the  differential  diagnoses  to  the
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ossibility  of  SOM.13,16 As  the  diagnosis  is  mainly  clinical
n  nature,  attentive  anterior  segment  examination  by  the
ye  professional  is  paramount  as  the  unilateral,  intermit-
ent,  low  amplitude,  high  frequency  cyclic,  intorsion/rotary
cular  movements  are  best  recognized  by  focusing  on  the
uperior  nasal  or  nasal  conjunctival  blood  vessels  during  the
lit  lamp  examination.2--4,13,15,16 Dynamic  viewing  is  the  best
ay  to  recognize  these  movements,  as  static  viewing  will
ot  help  elicit  movements  of  the  eye  itself.  It  is  important
o  differentiate  between  SOM  and  the  more  common,  eyelid
yokymia.  Even  with  attentive  investigation  and  high  suspi-
ion,  it  can  be  difﬁcult  at  best  to  identify  some  cases  other
han  with  a  good  case  history.15
ase report
 29-year-old  white  female  presented  for  examination  with
 complaint  of  monocular,  intermittent  oscillopsia  in  her
ight  eye  (OD)  only,  and  intermittent  vertical  and  diagonal
iplopia.  She  reports  that  her  symptoms  began  8--10  years
arlier,  but  that  she  had  noticed  a  signiﬁcant  worsening  over
he  previous  10  weeks  since  she  had  returned  to  work  from
aternity  leave.  She  reported  that  multiple  episodes  of
hese  visual  disturbances  occurred  unpredictably  on  a  daily
asis.  The  episodes  of  oscillopsia  seemed  to  worsen  when
eading  or  working  on  a  computer.  She  noticed  that  if  she
ilted  her  head  slightly  to  the  left  and/or  tilted  her  chin
p  so  she  was  looking  through  inferior  gaze,  her  symptoms
eemed  to  improve  most  days;  however,  these  maneuvers
id  not  always  eliminate/lessen  her  symptoms.  She  denied
ny  history  of  previous  or  current  headaches.  She  denied
aving  any  current  or  previous  systemic  issues  and  denied
eing  on  any  medications  or  eye  drops  altogether.  She  also
enied  any  history  of  surgeries  and/or  trauma  to  the  eyes  or
ead.  Family  medical  and  ocular  history  was  positive  only  for
laucoma  in  her  mother.  She  denied  any  history  of  multiple
clerosis  or  any  other  neurological  disorders  in  her  family.
he  patient  denied  alcohol,  tobacco,  nor  substance  abuse.
he  did  report  use  of  caffeine  on  a  daily  basis.  She  also
enied  having  any  drug/medical  allergies.
Entering  Snellen  visual  acuities  were  20/20  in  the  right
ye  (OD)  and  20/20  in  the  left  eye  (OS)  without  correc-
ion.  Pupils  were  equal,  round,  and  reactive  to  light  in
oth  eyes  in  both  light  and  dark  conditions  with  no  affer-
nt  pupillary  defect  in  either  eye.  Extraocular  motilities
ere  full  range  of  motion  in  all  diagnostic  action  ﬁelds  in
oth  eyes  (OU).  Confrontation  visual  ﬁelds,  color  vision,
nd  stereoacuity  testing  were  likewise  within  normal  limits
U.  Unilateral  and  alternating  cover  testing  failed  to  elicit
n  ocular  misalignment  as  the  patient  was  orthophoric  at
istance  and  near  without  correction,  with  no  evidence  of
ertical  misalignment  upon  testing.  The  remaining  exter-
al  and  dilated  fundus  exams  were  also  within  normal  limits
n  each  eye.  Intraocular  pressures  measured  via  Goldman
onometry  were  18  mmHg  OU.
The  patient  was  asked  to  return  in  a  few  days  for  a  more
n-depth  examination/workup  of  her  eyes  which  included:
dditional  cranial  nerve  testing  (V1,  V2,  V3,  and  VII),  formal
hreshold  Humphrey  SITA  threshold  24-2  visual  ﬁeld  test-
ng,  ocular  coherence  tomography  (OCT)  of  the  optic  nerves
nd  maculas,  fundus  photos,  vertical/horizontal  subjective
t
i
c
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addox  rod  testing  in  all  9  diagnostic  action  ﬁelds,  Park’s  3-
tep  tests,  vertical  fusion  amplitudes,  blood  pressure,  and
arginal  reﬂect  distances  (MRD1  and  MRD2).  All  above  test-
ng  returned  completely  within  normal  limits  in  both  eyes.
Fortunately,  at  this  visit  under  the  biomicroscope,  there
ere  noticeable  intermittent,  yet  rhythmic  intorsions,  and
ubtle  depressions  of  the  patient’s  OD.  These  intorsions
ere  of  low  amplitude,  yet  moderate  to  high  frequency.
o  such  response  would  be  found  in  the  OS,  which  was
onsistent  with  the  patient’s  self-reported  case  history  of
onocular  oscillopsia  of  the  OD.  Lastly,  the  following  blood
ests  were  ordered  to  help  rule  out  any  possible  underlying
nown  causes  of  ocular  motility  disorders:  complete  blood
ount  (CBC)  with  differential,  elevated  sedimentation  rate
ESR),  antinuclear  antibody  (ANA),  reactive  plasma  regain
RPR),  thyroid  panel  (TSH,  T3,  T4),  and  a  myasthemia  gravis
anel  including  anti-acetylcholine  receptor  antibodies.  All
abwork  returned  within  normal  limits  except  the  ANA  titer,
hich  was  reported  as  ‘positive’  by  the  laboratory  with
 1:40  ratio.  Subsequently,  given  the  marginally  increased
NA  titers,  double  stranded  DNA  (ds-DNA)  titers  were  also
rdered;  however,  these  ds-DNA  titers  were  negative.  Given
he  fact,  that  ANA  titers  can  be  slightly  elevated  in  about
5%  of  normal  individuals,  it  was  assumed  the  increased  ANA
as  non-speciﬁc/non-contributory  in  this  case  and  may  have
imply  been  a variant  of  normal.31
Due  to  the  recent  worsening  of  the  patient’s  symptoms,
he  patient  was  referred  to  our  local  neurology  clinic  for
urther  evaluation  and  neuro-imaging  given  the  possibility
f  ominous  causes  such  as  space  occupying  lesions,  multi-
le  sclerosis,  strokes,  and  arterio-venous  anomalies  in  other
eported  cases  of  SOM.13,14,16,18,22,29,30 Similar  to  our  exam-
nation,  the  neurologist  found  no  neurological  deﬁcits  on
is  exam;  however,  given  the  patient’s  symptoms  he  agreed
hat  neuro-imaging  was  required  to  rule  out  any  possible
minous  disorders.  Resultant  magnetic  resonance  imaging
MRI)  and  magnetic  resonance  angiograms  (MRA)  of  the  brain
nd  brainstem  returned  within  normal  limits.  Therefore,
he  patient  was  diagnosed  with  idiopathic  superior  oblique
yokymia.  Given  the  fact  that  a  few  case  reports  in  the  liter-
ture  highlight  relief  of  symptoms  in  some  patients  affected
y  SOM  with  the  use  of  -blockers,  such  as  propranolol
nd/or  topical  betaxolol,12 the  patient  in  this  case  study
as  prescribed  topical  timolol  ophthalmic  solution  (0.5%)
n  a  trial  basis  to  be  used  one  drop  twice  per  day  in  her  OD
nd  told  to  return  for  follow  up  in  4--6  weeks.  A follow-up
hone  call  four  weeks  later  revealed  the  patient  had  100%
elief  of  her  SOM  with  the  simple  use  of  topical  timolol  0.5%
nly  once  per  day  in  the  OD.  She  reported  that  after  only  1--2
ays  of  use  the  signs/symptoms  of  dizziness  and  oscillopsia
ompletely  disappeared  and  she  had  no  recurrences  since
tarting  the  timolol  drops  in  her  OD.  At  another  follow  up
hone  call  two  months  later  the  patient  reported  her  symp-
oms  were  still  completely  stable  with  no  recurrences.  She
as  asked  to  stop  the  timolol  drops  in  her  affected  eye  (OD)
nd  to  start  the  drops  in  the  opposite  eye  (OS)  to  see  if  any
ffect  could  be  found.  Within  two  days  of  attempting  to  do
his,  her  symptoms  returned  completely  in  her  OD  to  pre-
reatment  levels.  She  promptly  re-started  the  drops  again
n  the  OD  and  within  one  day  her  symptoms  disappeared
ompletely  again  and  she  has  had  no  further  recurrences
ince.  Given  her  very  satisfactory  treatment  and  drastic
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improvement  in  her  symptoms  she  was  told  to  continue  the
timolol  0.5%  drops  once  per  day  in  her  OD  and  to  return  for
follow  up  in  6--12  months  to  monitor  her  on-going  ocular
health  and  SOM  symptoms.
Pathogenesis of SOM
Historically,  hypotheses  regarding  the  pathogenesis  of  SOM
have  been  numerous  from  the  time  this  condition  was  ﬁrst
reported.  Originally,  Hoyt  et  al.  found  phasic  ﬁring  of  abnor-
mal  units  in  the  involved  superior  oblique  muscle  without
corresponding  inhibition  in  the  inferior  oblique  muscle  and
therefore  hypothesized  that  pathological  changes  in  the
membrane  threshold  of  neurons  in  the  trochlear  nucleus
itself  was  a  possible  explanation  indicating  that  SOM  is
primarily  a  trochlear  nucleus  disorder.2--5 A  second  hypoth-
esis  is  that  tetanic  bursts  of  action  potentials  may  arise
spontaneously  in  trochlear  neurons  or  axons  in  an  area  of
previous  injury/trauma  or  inﬂammation.13 Along  these  lines,
a  third  explanation  may  be  that  with  trauma  or  inﬂamma-
tion  a  loss  of  some  or  many  trochlear  axons  occurs  with
subsequent  peripheral  sprouting  of  remaining  axons  (neural
aberrant  regeneration)  and  may  result  in  the  development
of  a  few  large  motor  units  in  the  superior  oblique  muscle  in
an  attempt  by  the  trochlear  nerve  to  repair  itself.6,13 This
might  result  in  the  loss  of  ﬁne  voluntary  motor  control  of  the
superior  oblique  muscle  producing  a  microtremor  of  the  eye.
However,  this  fails  to  account  for  the  intermittent  nature  of
these  abnormal  eye  movements.6
Most  recently  however,  based  on  careful  MRI  imaging,
the  likely  and  most  currently  accepted  theory  regarding  the
mechanism  of  action  of  SOM  is  vascular  compression  of  the
trochlear  root  exit  zone  (REZ),  usually  from  branches  of  the
superior  cerebellar  or  posterior  cerebral  arteries.18,21--23 This
is  based  on  two  case  reports  of  neuro-surgical  microvas-
cular  decompression  surgeries  that  resulted  in  complete
elimination  of  SOM  symptoms.  This  is  very  similar  to  the
vascular  compression  mechanism  of  action  believed  to  be
caused  by  other  microvascular  contact  syndromes  such  as
glossopharyngeal  neuralgia,  hemifacial  spasm,  or  trigemi-
nal  neuralgia.21--23 Thinly  sliced  images  (1.0--2.0  mm  versus
10.0  mm  slices  in  conventional  MRI)  are  best  as  this  gives  the
investigation  team  the  best-detailed  views  in  order  to  detect
subtle  neuro-anatomical  problems  such  as  vascular  compres-
sion  of  the  trochlear  nerve  at  its  root  exit  zone  (REZ).18 If
the  MRI-slices  are  too  large  then  subtle  vascular  compression
may  be  missed  on  review  of  the  MRI.  Vascular  compression  is
deﬁned  on  neuro-imaging  as  the  absence  of  any  detectable
layer  of  cerebrospinal  ﬂuid  between  the  trochlear  nerve  and
an  adjacent  blood  vessel,  often  a  branch  of  the  superior
cerebellar  or  posterior  cerebral  artery.18,21
Interestingly,  a  history  of  head  trauma  is  often,  but  not
always,  found  in  patients  with  SOM,6,7,11,13,14,19,23,25 which
raises  the  question  of  trauma  being  an  explanation  and/or
alternate  pathway  for  SOM  other  than  the  vascular  compres-
sion  theory.  One  study  looked  at  the  morphological  structure
of  two  patients  (one  with  head  trauma  and  the  second
with  trauma  iatrogenically  induced  to  the  trochlear  nerve)
with  SOM  via  MRI  and  found  that  the  affected  superior
obliques  in  both  patients  were  statistically  smaller  in  over-
all  size/diameter  than  normal  eyes.  Although  this  study  only
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ad  two  patients,  the  authors  suggested  that  trauma/injury
esults  in  damage  to  the  trochlear  nucleus  or  its  axons
ead  to  possible  atrophy  of  the  superior  oblique  muscle.14
hen  they  suggest  that  resultant  aberrant  nerve  regener-
tion  causes  a  defective  ﬁring/contracting  of  the  involved
uperior  oblique,  which  may  cause  the  symptoms  related
o  SOM.14 Although  the  exact  role  of  head  trauma  is  cur-
ently  unclear  in  SOM,  it  is  this  author’s  hypothesis  that
erhaps  vascular  compression  and  trauma  are  two  separate
auses  of  SOM  with  a  ﬁnal  common  pathway  resulting  in  SOM
ymptoms  in  these  patients.  Perhaps  the  traumatic  event  in
ome  patients  actually  causes  the  vascular  compression  of
he  REZ  leading  to  SOM.  However,  it  remains  unclear  at  this
oint  how  trauma  and  vascular  compression  of  the  trochlear
erve’s  REZ  are  related,  if  at  all,  and  this  theory  is  currently
othing  more  than  an  interesting  observation  and  idea  by  the
uthor.
Also  historically,  the  vast  majority  of  SOM  cases  have
een  idiopathic  and  overall  benign  in  nature.  However,  there
re  case  reports  in  the  literature  caused  by  more  omi-
ous  causes,  albeit  much  rarer,  such  as  multiple  sclerosis,
erebellar  tumors,  stroke,  arterio-venous  malformations,
rauma,  cerebellopontine  arachnoid  cysts,  adrenoleucodys-
rophy  (hereditary  metabolic  neurodegenerative  disease),
stulas,  hydrocephalus,  iatrogenic,  etc.13,14,16,18,22,29,30 Older
esearchers  have  advocated  foregoing  neuro-imaging  sec-
ndary  to  the  very  uncommon  yield  of  ﬁnding  an  underlying
athology;13 however,  newer  researchers  suggest  neuro-
maging  for  all  new  cases  of  SOM  given  the  possibility
f  vascular  compression  and  of  the  other  possible  omi-
ous  underlying  neurological  causes  mentioned  above,  even
hough  the  ominous  causes  are  much  rarer.21,27
anagement/treatment options of SOM
fter  ruling  out  or  identifying  possible  underlying  causes
entioned  earlier,  management  typically  follows  this
ethodical  and  logical  treatment  paradigm:  observation,
edical  management,  and  surgical  intervention.13--15,21 For
atients  who  notice  symptoms  but  yet  can  function  ade-
uately  in  their  day-to-day  lives,  simple  observation  by  the
octor  and  reassurance  for  the  patient  may  be  all  that  is
equired  as  long  as  rarer,  more  ominous  causes  are  ruled
ut.23
For  patients  whose  symptoms  are  more  troubling  and
hose  symptoms  interfere  with  their  occupation  or  activi-
ies  of  daily  living,  medical  intervention  followed  by  surgical
ntervention  is  indicated.3,4 In  some  cases  simple  ground-
n  prism  (base  down  over  the  hyper-deviated  eye)  in  the
atient’s  habitual  spectacle  prescription  has  provided  relief
f  symptoms.8 Medical  management  historically  has  been
lmost  exclusively  the  domain  of  oral  drugs.  Pharmaco-
ogic  therapy  is  directed  at  diminishing  the  frequency  of
athologic  bursts  of  ﬁring  of  the  trochlear  nerve;  how-
ver,  the  mechanism  of  action  (MOA)  of  these  drugs  in
egards  to  SOM  are  not  yet  fully  known,  although  they
re  believed  to  simply  be  an  extension  of  their  regular
OA.9 The  original/prototypical  drug  used  for  SOM  was
arbamazepine,3--6,9,15,19 but  with  its  use  comes  serious
otential  side  effects  such  as  leukopenia,  acute  renal  fail-
re,  thromboembolism,  and  arrhythmias.3,4,26 Therefore,
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ther  alternative  oral  medications  have  been  compared,
ttempted,  and  investigated  over  the  past  30+  years.  In
007,  Williams  et  al.  retrospectively  studied  a  group  of  20
ndividuals  with  SOM  who  were  treated  with  different  oral
edications  to  determine  which  medication  was  best  at
elieving  patients’  symptoms.  In  their  retrospective  study,
0%  (18  of  20)  of  SOM  patients  were  started  on  200  mg  car-
amazepine  twice  per  day  then  titrated  up  to  200  mg  four
imes  per  day  which  resulted  in  relief  for  83%  (15  of  20)
f  the  patients.25 Overall,  80%  of  patients  treated  med-
cally  experienced  a  positive  response  to  some  degree.25
hey  noted  that  baclofen  did  not  relieve  the  symptoms  of
ny  patients  in  the  study,  which  has  also  been  found  in  sev-
ral  other  studies.5,25 Propranolol  and  phenytoin  were  two
ther  medications  attempted  but  with  mixed  results  at  best.
nfortunately,  this  study  did  not  discuss  on  the  efﬁcacy  of
opical  -blockers,  gabapentin,  or  memantine  as  none  of  the
atients  in  the  retrospective  study  were  treated  with  any  of
hese  medications.  Of  the  six  patients  in  this  study  who  dis-
ontinued  medication  secondary  to  side  effects,  all  of  them
ere  on  carbamazepine.25
Subsequently,  other  oral  medications  have  been  tried  and
nvestigated  by  other  case  reports  and  studies  in  order  to
nd  a  way  to  decrease  symptoms  and  limit  side  effects  at  the
ame  time,  but  some  have  had  varying  degrees  of  success.
hese  oral  medications  have  included:  phenytoin,  propra-
olol,  baclofen,  gabapentin,  clonazepam,  mirtazapine,  and
ost  recently  memantine.7,10,13,15,19,21--26
Surgical  intervention  is  reserved  only  for  those  cases  in
hich  the  patient  is  very  symptomatic  and  topical  and/or
ral  medications  have  failed  to  provide  improvement/relief
or  the  patient.3,4,27,28 Originally,  the  ﬁrst  surgical  treat-
ents  attempted  were  tenotomy  (complete  severance)  of
he  superior  oblique  tendon  followed  by  recession  (replace-
ent  of  eye  muscle  at  a  different  location  on  the  globe
esigned  to  weaken  the  action  of  the  involved  muscle)  or
yectomy  (removing  a  portion  of  the  muscle  belly  to  weaken
ts  action)  of  the  ipsilateral  inferior  oblique  muscle.4,9,11,23,27
ore  recent  studies/case  reports  appear  to  favor  tenec-
omy  (partial  severance)  of  the  superior  oblique  tendon,7
ollowed  by  myectomy  (removing  a  portion  of  the  muscle
elly  in  order  to  weaken  the  muscle)  of  the  ipsilateral  infe-
ior  oblique  muscle.11,13,23,27,28 Although  this  more  recent
pproach  of  tenectomy  followed  by  myectomy  is  typically
ery  successful  in  eliminating  oscillopsia,  it  can  induce
iplopia  in  downgaze  secondary  to  iatrogenic  trochlear
erve  palsy  and  resultant  hypertropia  in  35%  of  patients,  but
his  can  usually  be  ﬁxed  with  prism  correction  if  needed.28
lthough  surgery  can  be  curative  in  some  cases,  some
atients  may  still  suffer  with  lingering  oscillopsia  or  diplopa
ven  after  surgery.  In  some  cases,  additional  surgery  may
e  needed  which  may  or  may  not  result  in  elimination  of
he  patient’s  symptoms.7,11 Therefore,  a  detailed  explana-
ion  highlighting  pros/cons,  side  effects,  and  risk  of  further
urgery  needs  to  be  done  with  the  patient.  Some  authors
ave  also  advocated  the  combination  of  superior  oblique
yectomy  and  resection  of  the  trochlea  via  anterior  orbito-
omy  if  tenectomy  fails  from  the  ﬁrst  operation.9,27 Others
ave  advocated  a  special  hybrid  tenectomy  approach  known
s  the  Harada-Ito  Procedure.15 In  the  Harada-Ito  proce-
ure,  the  anterior  aspect  of  the  superior  oblique  is  recessed
asally  to  weaken  the  torsional  function  while  not  affecting
o
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he  vertical  function  of  the  muscle.15,23 Still  others  have
lso  advocated  the  injection  of  botulinum  toxin  in  to  the
uperior  oblique  muscles,  but  given  the  possibility  of  the
njection  also  spreading  to  other  ocular  muscles  such  as  the
evator  and  superior  rectus,  this  is  not  done  as  a  ﬁrst  line
reatment.9
In  cases  of  structural  brain/brainstem  lesions  or  vas-
ular  compressions,  neurosurgery  is  also  sometimes,  but
ery  rarely,  indicated  to  relieve  symptoms  or  prevent  possi-
le  life-threatening  complications  depending  on  the  lesion’s
ause.16,17,30 In  cases  of  vascular  compression,  microvas-
ular  decompression  surgery  (MDS)  is  performed.  In  MDS,
he  trochlear  nerve  is  identiﬁed  and  followed  to  its  root
xit  zone  (REZ).  Then,  any  vein  or  artery  compressing  the
erve  is  dissected  free  and  Teﬂon  pads  are  placed  to  pre-
ent  any  further  compression.  Only  two  known  patients
ave  undergone  this  procedure;  however,  both  procedures
liminated  the  SOM  symptoms  completely,  but  induced  per-
anent  trochlear  nerve  palsies  in  both  patients  which  could
e  managed  with  prismatic  corrections.17,23 The  success-
ulness  of  this  procedure  in  eliminating  the  patients’  SOM
ymptoms  is  strong  for  the  vascular  compression  theory  of
OM.  Overall,  the  bulk  of  the  ophthalmic  literature  would
gree  with  the  viewpoint  that  invasive  craniotomy  surgi-
al  procedures  should  be  justiﬁed  only  by  the  presence  of
ntractable  and  absolutely  unbearable  symptoms.21,23 In  the
nd,  the  decision  for  surgery  regarding  SOM  of  any  kind
hould  be  based  on  the  known  etiology  of  the  SOM  and  only
fter  topical  and  oral  medications  have  failed  to  yield  sub-
tantial  improvement  in  the  patients’  symptoms  to  the  point
hat  the  patient  cannot  function  appropriately  in  their  day-
o-day  lives  because  of  their  debilitating  symptoms.
opical timolol as a novel treatment idea in
OM
nterestingly,  in  1994,  Bibby  et  al.  described  resolution  of
 patient’s  symptoms  from  SOM  with  the  use  of  a  topical
-blocker,  betaxolol,  a well-known  glaucoma  drug.12 This
as  based  on  case  reports  of  success  in  some  patients  with
he  use  of  betaxolol’s  parental/prototypical  drug,  propra-
olol,  and  one  other  study  that  reported  some  improvement
ith  topical  -blockers.12,23 The  exact  mechanism  of  action
egarding  topical  -blockers  in  SOM  is  currently  unknown;
owever,  it  is  theorized  that  it  is  secondary  to  the  weak
embrane-stabilizing  abilities  of  this  class  of  drugs.12 Bibby
t  al.  hypothesized  that  enough  betaxolol  may  be  absorbed
ystemically  through  the  ocular  blood  vessels  to  eliminate
he  SOM.12 However,  this  author  hypothesizes  that  the  weak
embrane-stabilizing  properties  of  -blockers  do  not  nec-
ssarily  work  on  a  systemic  level  but  rather  locally  on  the
rochlear  nerve  endings  and  superior  oblique  muscle  tis-
ues,  which  in  turn  slows  down  or  eliminates  the  rhythmic
ontractions  of  the  superior  oblique  muscle,  much  like  -
lockers/antagonists  do  to  cardiac  muscle  tissue  in  patients
ith  hypertension.  This  ‘‘localized  theory’’  is  supported  by
he  patient  in  this  particular  case  study  as  her  symptoms
f  SOM  returned  within  two  days  of  stopping  the  drops  in
he  affected  eye  (OD)  but  also  while  using  the  drops  in  the
ame  manner  in  the  opposite  eye  (OS)  as  she  had  previously
one  in  the  right  eye  (OD).  If  the  topical  drops  are,  indeed,
CT
a
S
n
t
t
l
o
e
t
n
o
s
a
d
s
s
A
t
c
s
d
i
w
p
m
t
o
t
m
t
o
m
c
n
b
t
m
w
p
b
h
t
s
b
t
w
G
s
t
c
sA  review  and  potential  use  of  topical  timolol  
absorbed  systemically  to  a  concentration  high  enough  to
elicit  an  effect,  then  switching  the  instillation  of  the  drops
between  the  two  eyes  would  have,  logically,  also  controlled
the  patient’s  symptoms.  But  in  this  case  report,  her  symp-
toms  of  SOM  returned  in  severity  to  pre-treatment  levels
and  showed  no  beneﬁt  at  all  when  the  timolol  was  used  in
the  contralateral  eye.  This  would  suggest  that  a  localized
effect  with  topical  -blockers  at  the  trochlear  nerve  endings
and/or  superior  oblique  tissues  themselves  is  responsible
for  the  treatment  effect,  not  systemically  as  Bibby  et  al.
originally  hypothesized.
Although  there  are  cases  of  idiopathic  SOM  resolving  on
its  own  over  a  period  of  months  to  years,  this  is  unlikely  to
occur  in  this  case  report  as  the  patient  reported  her  symp-
toms  had  started  over  8  years  previous  to  her  presentation  to
our  clinic  and  seemed  to  be  getting  worse  according  to  her
case  history,  but  stopped  1--2  days  after  starting  her  topical
timolol  eye  drops.  In  addition  to  this,  her  symptoms  returned
after  discontinuing  the  drops  in  her  affected  eye  and  com-
pletely  stopped  again  when  the  drops  were  re-started  in
the  affected  eye.  Although  the  number  of  cases  that  report
actual  improvement  with  topical  -blockers  is  sparse  at  best
in  the  literature,  topical  -blocker  use  is  an  interesting  and
relatively  novel  treatment  idea  that  may  lend  relief  to  SOM
sufferers  as  it  did  in  this  case  report.
Potential new observations in SOM
A  notable  observation  found  by  the  author  in  the  patient  of
this  case  report  was  that  her  symptoms  seemed  to  worsen
postpartum,  which  raises  the  question  of  whether  pregnancy
and/or  hormones  could  be  a  trigger  factor  in  SOM.  Inter-
estingly,  in  the  author’s  review  of  the  literature  on  SOM,
other  separate  case  reports  over  the  years  have  only  pas-
sively  mentioned  a  return  or  start  of  patients’  SOM  symptoms
shortly  after  becoming  pregnant  or  shortly  postpartum,  but
none  ever  ventured  to  say  that  one  may  be  associated  with
the  other.9,10,22 To  the  author’s  knowledge,  no  other  stud-
ies  have  mentioned  or  discussed  this  possible  link  with  SOM
speciﬁcally  either.  If  pregnancy  is  found  to  be  a  risk  fac-
tor  or  is  involved  somehow  with  SOM,  this  may  obviously
help  explain  why  females  are  affected  by  SOM  much  more
commonly  than  males.  A  possible  link  between  SOM  and
pregnancy/hormones  is  complete  speculation  on  the  part  of
the  author  at  this  time,  but  it  may  be  an  interesting  point  to
investigate  with  other  studies  in  the  future  as  possible  risk
factors,  associations,  or  triggers  for  SOM.
Lastly,  trauma  has  been  shown  to  be  associated  with  SOM
as  well.  Given  that  men  tend  to  engage  in  higher  risk  activi-
ties  than  women,  perhaps  cases  of  SOM  in  men  may  be  more
trauma-related,  and  perhaps  cases  of  SOM  in  women  may
be  more  hormone/pregnancy  related,  but  they  may  share
a  ﬁnal  common  pathway  resulting  in  the  symptoms  of  SOM.
At  this  time,  this  is  strictly  an  observation  from  the  litera-
ture  and  is,  again,  complete  speculation  at  this  point  on  this
author’s  part.  Further  studies  will  be  necessary  to  reveal  the
underlying  reason  why  women  are  more  afﬂicted  than  men
with  SOM  and  if  trauma,  hormones,  or  pregnancy  even  play
a  role  at  all  in  the  pathogenesis  of  SOM.
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onclusion
his  case  is  interesting  and  important  because  it  provides
nother  example  to  the  overall  low  reported  numbers  of
OM  being  successfully  managed  with  only  topical  eye  drops,
otably  a  common  topical  -blocker,  timolol  0.5%.  Although
his  is  only  one  case  report,  SOM  is  a  rare  ocular  condi-
ion  at  best.  Given  the  overall  rarity  of  SOM  but  relatively
imited  treatment  options  other  than  the  standard  battery
f  oral  medications  with  the  possibility  of  signiﬁcant  side
ffects,  it  would  be  ideal  if  a  topical  medication  is  available
o  treat  SOM.  Although,  to  the  author’s  knowledge,  there  has
ot  been  any  formal  study  investigating  the  total  efﬁcacy
f  topical  timolol  in  the  management  of  SOM  in  compari-
on  to  other  medications  used  historically  for  SOM,  it  is  the
uthor’s  viewpoint  that  timolol  is  a  very  well  understood
rug  in  the  eye  care  community  and  that  it  may  provide  a
imple,  safe,  ﬁrst-line  treatment  option  in  cases  of  SOM  for
ome  patients  that  should  be  evaluated  in  future  studies.
dmittedly,  in  this  speciﬁc  case,  there  was  only  one  patient
reated  successfully  with  this  drug,  therefore  the  author
annot  entirely  omit  the  placebo  effect  so  solid  conclu-
ions  cannot  be  extracted  about  the  real  effect  of  this  drug
espite  the  drug’s  rather  robust  effect  for  the  patient.  More
n-depth  study  is  needed  to  conclude  with  any  certainty
hether  topical  timolol  would  indeed  be  an  upgrade  over
reviously  tried  oral  medications.
In  the  event  of  medical  management  failure,  surgery
ay  be  considered;  however,  it  does  have  serious  poten-
ial  risks  involved.  Surgery  should  only  be  done  in  the  event
f  absolutely  unbearable  symptoms  and  only  after  several
opical  and/or  oral  medications  have  been  attempted.  This
ethodical  treatment  approach  (observation,  medications,
hen  surgery)  allows,  at  least  theoretically,  the  least  risk
f  side  effects  from  all  medications.  As  most  of  these  oral
edications  may  be  out  of  the  comfort  zones  of  most  eye-
are  providers,  an  appropriate  referral  to  a  neurologist  or
euro-ophthalmologist  familiar  with  these  medications  may
e  necessary  at  the  point  of  topical  -blocker  failure.
In  the  acute  setting,  eyecare  providers  should  be  able
o  identify  SOM  in  a  timely  manner  and  rule  out  the  rarer,
ore  ominous  causes  of  SOM  with  neuro-imaging  and  blood-
ork  with  either  a  neurologist  or  the  patient’s  primary  care
rovider.  A  history  of  head  trauma,  even  years  earlier  should
e  sought  by  the  examiner  during  the  case  history  as  this
as  a  close  association  with  SOM  in  some  patients.  Then,
he  eyecare  provider  should  focus  on  managing  the  patient’s
ymptoms  with  medications  if  an  underlying  disorder  cannot
e  found.  The  patient  in  this  case  study  has  been  symp-
om  free  for  4  months  duration  at  the  time  of  this  paper
ith  the  use  of  daily  topical  timolol  in  her  affected  eye.
iven  her  normal  neuro-imaging  studies  and  bloodwork,
he  will  be  followed  closely  and  will  be  referred  back  to
he  neurologist  for  a  trial  of  oral  medications  if  her  topi-
al  timolol  eyedrops  fail  to  provide  continued  relief  of  her
ymptoms.onﬂicts of interest
he  author  has  no  ﬁnancial  or  any  other  conﬂict  of  interest
o  report.
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